A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan(T-DXd) Monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11)

Condition: High-risk HER2-positive Early-stage Breast Cancer

Sponsor: AstraZeneca

Phase: 3

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan(T-DXd) Monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with High-rosk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11). DESTINY-Breast 11 is a global, open-label, multicentre, randomized, 3-arm Phase 3 study to determine the efficacy and safety of T-DXd monotherapy or T-DXd followed by THP as neoadjuvant treatment compared to ddAC-THP in participants with locally advanced or inflammatory HER2-positive, high-risk (lymph node positive [N1-3] or with a primary tumour stage T3-4) EBC.